A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02864290
- Locations
- 🇺🇸
Site US00006, Duarte, California, United States
🇺🇸Site US00003, Baltimore, Maryland, United States
🇺🇸Site US00007, Boston, Massachusetts, United States
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
- Conditions
- Peanut Allergy
- Interventions
- Drug: ASP0892 IntramuscularDrug: ASP0892 IntradermalDrug: Placebo IntradermalDrug: Placebo Intramuscular
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02851277
- Locations
- 🇺🇸
Site US10014, Little Rock, Arkansas, United States
🇺🇸Site US10008, Mountain View, California, United States
🇺🇸Site US10001, Baltimore, Maryland, United States
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT02799745
- Locations
- 🇺🇸
Site US10034, Birmingham, Alabama, United States
🇺🇸Site US10024, Homewood, Alabama, United States
🇺🇸Site US10007, Tucson, Arizona, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Conditions
- Benign Prostatic HyperplasiaOveractive Bladder
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 715
- Registration Number
- NCT02757768
- Locations
- 🇺🇸
Site US01009, Homewood, Alabama, United States
🇺🇸Site US01005, Huntsville, Alabama, United States
🇺🇸Site US01012, Anchorage, Alaska, United States
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT02752035
- Locations
- 🇺🇸
UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸University of California, Irvine Medical Center, Orange, California, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 599
- Registration Number
- NCT02723591
- Locations
- 🇺🇸
Site US10006, Birmingham, Alabama, United States
🇺🇸Site US10025, Scottsdale, Arizona, United States
🇺🇸Site US10031, Los Angeles, California, United States
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02720263
- Locations
- 🇺🇸
Site US10001, Glendale, California, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02698657
- Locations
- 🇺🇸
Site US10002, Anniston, Alabama, United States
🇺🇸Site US10008, DeBary, Florida, United States
🇺🇸Site US10004, Jacksonville, Florida, United States
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Conditions
- Metastatic Hormone Sensitive Prostate Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1150
- Registration Number
- NCT02677896
- Locations
- 🇺🇸
Site US10016, Homewood, Alabama, United States
🇺🇸Site US10007, Anchorage, Alaska, United States
🇺🇸Site US10008, Tucson, Arizona, United States
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
- Conditions
- Epidermal Growth Factor Receptor (EGFR) MutationsSolid Tumors
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT02674555